Method for obtaining tgRNA through novel chimeric tRNA-sgRNA
By integrating the sgRNA sequence into the anticodon arm of tRNA, it forms a chimeric tgRNA platform and co-expresses it with the dCas protein, the problem of insufficient sgRNA stability and expression in the prior art is solved, and the gene editing of the CRISPR/Cas system is significantly improved Efficiency and specificity provide more efficient and stable tools for gene editing technology.
Patent Information
- Application Number
- CN202411125693.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-16
- Publication Date
- 2024-11-22
AI Technical Summary
The existing tRNA-sgRNA tandem mode fails to fully utilize the structural advantages of tRNA, resulting in insufficient stability and expression of sgRNA, affecting the gene editing efficiency and specificity of the CRISPR/Cas system.
Integrate the sgRNA sequence into the anticodon arm of tRNA to form a new chimeric tgRNA platform, enhance the stability and expression of sgRNA, and co-expression with dCas protein through CRISPRi technology to inhibit DNA transcription and improve the accuracy of gene editing.
It significantly improves the gene editing efficiency and specificity of the CRISPR/Cas system, reduces non-target effects, and achieves more efficient and stable gene editing tools, suitable for precise gene operation in medicine, agriculture and other fields.
Smart Images

Figure CN118995706A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of gene editing and molecular biology, and specifically relates to the establishment and application of a novel chimeric tRNA-sgRNA (tgRNA) platform improved in CRISPR / Cas. Background Art
[0002] CRISPR / Cas is a gene editing technology that uses Cas proteins and sgRNA to accurately identify and cut target DNA. sgRNA contains a guide sequence that pairs with the target DNA and a backbone structure for binding to Cas, and is a core component in the CRISPR system. The stability and expression level of sgRNA directly affect the efficiency and specificity of CRISPR / Cas-mediated gene editing. Studies have shown that improving the stability of sgRNA can significantly reduce off-target effects and improve the cutting efficiency of target DNA. Therefore, enhancing the stability and expression of sgRNA is the key to improving the editing efficiency of CRISPR / Cas9.
[0003] tRNA has inherent high stability and high expression rate due to its compact three-dimensional structure, which can effectively resist degradation. The production of multiple sgRNAs in a single transcript through the tRNA-sgRNA tandem system has been shown to have the potential to improve the efficiency of CRISPR / Cas9 and Cpf1-mediated gene editing in multiple systems, but these methods have not yet fully utilized the structural advantages of tRNA.
[0004] Based on this, we proposed the construction of a new chimeric tgRNA platform. Its innovation lies in the integration of the sgRNA sequence into the anticodon arm of the tRNA template. This structural innovation not only maintains the structural integrity of tRNA, but also significantly enhances the stability and expression of sgRNA, providing a more efficient and stable gene editing tool for the CRISPR / Cas system. This new chimeric tgRNA platform can be widely used in research fields such as medicine and agriculture, including the construction of complex disease models, the improvement of crop traits, and the realization of precise gene manipulation in multiple species such as animals and plants, providing new possibilities for gene editing technology. Summary of the invention
[0005] Purpose of the invention: The first is to provide a new type of chimeric tRNA-sgRNA (tgRNA) CRISPR / Cas platform.
[0006] Second, it provides the application of a new chimeric tgRNA platform for CRISPR / Cas technology.
[0007] The present invention discloses a novel method for obtaining tgRNA from chimeric tRNA-sgRNA, comprising the following steps: Using the RISPR / Cas sgRNA mutagenesis kit, the guide N20 region targeting E. coli genes was inserted into the pTargetF vector (Addgene #62226) to construct sgRNAs targeting these genes.
[0008] The vector for inserting sgRNA can also be selected from pUC19 vector or pBR322 vector.
[0009] To construct the tRNA scaffold, synthesize a DNA sequence encoding the modified tRNA: gcccggataggctcgcggtagagcgcgcgcggccgagtagtagtagcgacggtgcgatggttggcgcgcggggtcggtcagtcagtcatcagtcagggtcagtgaggcgcggacgcgcgagcgcgaggacggacggtgacgcggtgag; The tRNA scaffold is derived from tRNA of any species among bacteria, fungi, animals and plants.
[0010] Construct pTargetF vector containing tgRNA and transform it into Escherichia coli K12MG1655 The steps for expressing in strains are as follows: A) The sequence was cloned into the pTargetF vector downstream of the pij23115 promoter and upstream of the rrnc terminator using SpeI and PstI restriction enzymes to generate the pTargetT vector; B) To produce chimeric tgRNAs, sgRNA sequences targeting different genes were amplified from pTargetF containing sgRNA and cloned into the SalI and AatII sites of pTargetT vector to generate pTarget-tg vector.
[0011] C) Use of E. coli DH5α To clone the host.
[0012] In addition to the pTargetF vector, pBluescript or pGEM vectors can also be used.
[0013] The expression of chimeric tgRNA was detected by Northern blot, and the steps were as follows: A) Cells were harvested from cells transduced with the relevant constructs and total RNA was extracted using TRIzol reagent.
[0014] B) For each sample, 10 μg of RNA was denatured by heating to 95 ˚C for 5 minutes.
[0015] C) The samples are then loaded onto a denaturing urea PAGE gel of the appropriate percentage to efficiently resolve RNAs of different sizes.
[0016] D) After electrophoresis, RNA was transferred to a Hybond-N+ nylon membrane using a semi-dry transfer system.
[0017] E) The membrane was UV cross-linked and then hybridized overnight with biotinylated probes specific for tracer RNA (5'-tttttt-caagttgatacacgactagctttttttacataattt-3') and 5S RNA (5'-gagaccaccaccaccatcg-5'), the latter serving as a loading control.
[0018] F) After washing, the membrane was incubated with horseradish peroxidase (HRP)-conjugated streptavidin and detected using an enhanced chemiluminescence (ECL) kit.
[0019] Construct inactivated dCas protein and express and verify the protein; A) Use a site-directed mutagenesis kit to generate dCas variants.
[0020] B) Transformation of pdCas into E. coli K12MG1655 in competent cells.
[0021] C) Cells were cultured in Luria-Bertani medium supplemented with kanamycin (50 μg / mL) and 0.4 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at 30 ˚C for 24 hours to induce dCas expression under controlled conditions.
[0022] D) The cells were then harvested and resuspended in PBS, pH 7.4.
[0023] E) After sonication and centrifugation, the supernatant containing dCas protein was loaded onto a 10% SDS-PAGE gel for electrophoresis.
[0024] F) Proteins were transferred to polyvinylidene difluoride (PVDF) membrane using a standard wet transfer system.
[0025] G) The membrane was blocked and incubated with anti-Cas mouse monoclonal antibody.
[0026] H) After washing, HRP-conjugated rabbit anti-mouse antibody was added and detected using ECL Western blotting Luminol reagent.
[0027] Using CRISPRi technology, chimeric tgRNA was co-expressed with dCas to inhibit DNA transcription, as follows: A) Preparation of Escherichia coli carrying pdCas K12MG1655 Determination of CRISPRi effects in chemically competent cells.
[0028] B) Plasmids pTargetF, pTargetT, and pTarget-tg were transformed into these competent cells respectively.
[0029] C) Cells were grown in Luria-Bertani medium supplemented with kanamycin (50 μg / mL), spectromycin (50 μg / mL), and 0.4 mM IPTG at 30 ˚C for 24 hours.
[0030] D) After incubation, total RNA was extracted from harvested cells and then reverse transcribed into cDNA using the qScript Flex cDNA Kit.
[0031] E) The resulting cDNA is then used as a template for quantitative real-time PCR using gene-specific primers designed for the targeted gene.
[0032] F) qPCR conditions were optimized for each target to accurately quantify CRISPRi-mediated knockdown efficiency.
[0033] The innovation of the present invention lies in: 1. Compared with the traditional tRNA-sgRNA tandem model, the present invention makes fuller use of the structural advantages of tRNA and improves the editing efficiency of the CRISPR / Cas system; 2. Different from the widely used tRNA-sgRNA tandem mode, the present invention inserts sgRNA into the anticodon arm of tRNA to form a new chimeric tgRNA, which significantly enhances the stability and expression of sgRNA, thereby significantly reducing non-target effects and improving the cutting efficiency of target DNA; 3. The present invention uses CRISPRi technology to co-express tgRNA with dCas protein, effectively inhibiting DNA transcription, reducing the difficulty of target recognition and binding that may be caused by molecular steric hindrance, and improving targeting accuracy; 4. The present invention provides a more efficient and stable gene editing tool for the CRISPR / Cas multiplex system.
[0034] 5. The present invention can be widely used in research fields such as medicine, agriculture and biology, including the establishment of complex disease models, the improvement of crop traits and the realization of precise gene manipulation in multiple species such as plants and animals, thus providing new possibilities for gene editing technology. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1 Generation of chimeric SeptgRNA.
[0036] Figure 2 SeptRNA expression and Northern blot analysis.
[0037] Figure 3 Gel electrophoresis of SeptRNA and SeptgRNA.
[0038] Figure 4 qPCR analysis of SeptgRNA and corresponding sgRNA.
[0039] Figure 5 ampC and ompA qPCR analysis of gene expression levels. DETAILED DESCRIPTION
[0040] In order to more clearly explain the purpose, technical solution and advantages of the present invention, a detailed description will be given in conjunction with the drawings in the embodiments of the present invention. It should be pointed out that the embodiments only represent some embodiments of the present invention, not all. Based on these embodiments, other embodiments such as changes, equivalent replacements and technical improvements of the present invention should be deemed to be within the scope of protection of the present invention.
[0041] In the prior art, tRNA and sgRNA are usually used in tandem, and this method has not fully utilized the structural advantages of tRNA. In order to solve this technical problem, the present invention proposes a novel chimeric tRNA-sgRNA (tgRNA) CRISPR / Cas system construction and application method. Compared with the traditional tRNA-sgRNA tandem use, this method significantly improves the stability and expression of sgRNA by directly embedding the sgRNA sequence into the anticodon arm of tRNA. This enhanced expression and stability not only reduces non-target effects, but also improves the cutting efficiency of target DNA, thereby significantly enhancing the overall efficiency of gene editing.
[0042] Example 1: Targeting Escherichia coli using novel chimeric tgRNA ampC (1) Using the CRISPR / Cas9 sgRNA mutagenesis kit, target Escherichia coli ampCThe guide N20 region of the gene (cactcaaactacacatacg) was inserted into the pTargetF vector (Addgene #62226) to construct the sgRNA targeting this gene.
[0043] (2) Construct the pTargetF vector containing SeptgRNA and transform it into Escherichia coli K12MG1655 expressed in strains.
[0044] A) This sequence was cloned into the pTargetF vector downstream of the pij23115 promoter and upstream of the rrnc terminator using SpeI and PstI restriction enzymes to generate the pTargetT vector, which is expressed as Figure 2 As shown in A; B) To generate chimeric SeptgRNAs, the targeting locus was amplified from pTargetF containing the sgRNA. ampC sgRNA sequence and cloned it into the SalI and AatII sites of the pTargetT vector to obtain the pTarget-tg vector, which is expressed as Figure 2 As shown in B.
[0045] C) Use of E. coli DH5α strain as the cloning host.
[0046] (3) A novel SeptgRNA with an optimized sgRNA inserted into the anticodon arm of SeptRNA ( ampC ),like Figure 1 As shown, the sequence is as follows: gcccggauagcucagucgguagagcagcggccgaguaauuuacgucgaccacucaaacucaaccauacgguuuuuagagcuagaaauagcaguuaaaauaaggcuaguccguuau caacuugaaaaaguggcaccgagucggugcgacgucgaugguugcggccgcggguccaggguucaagucccuguucgggcgccacagcugcagauccuuagcgaaagcuaagga (4) Use Northern blot to detect the expression of SeptgRNA, such as Figure 2 As shown in C.
[0047] A) The pCas vector (Addgene #62225) was modified using the QuikChange Lightning Site-Directed Mutagenesis Kit by replacing Asp10 and His840 with alanine to generate dCas9 variants whose sequences are as follows:
[0048] B) Transformation of pdCas into E. coli K12MG1655 in competent cells.
[0049] C) Cells were cultured in Luria-Bertani medium supplemented with kanamycin (50 μg / mL) and 0.4 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at 30 ˚C for 24 hours to induce dCas9 expression under controlled conditions.
[0050] D) Harvest cells and resuspend them in PBS, pH 7.4.
[0051] E) After sonication and centrifugation, the supernatant containing dCas9 protein was loaded onto a 10% SDS-PAGE gel for electrophoresis.
[0052] F) Transfer the protein to a polyvinylidene difluoride (PVDF) membrane using a standard wet transfer system.
[0053] G) The membrane was then blocked with 5% nonfat milk for 1 hour at room temperature and then incubated with anti-Cas mouse monoclonal antibody (1:1000 dilution) at 4°C overnight.
[0054] H) After washing, HRP-conjugated rabbit anti-mouse antibody was added and detected using ECL Western Blot Luminol reagent.
[0055] (5) Using CRISPRi technology, DNA transcription is inhibited by co-expressing tgRNA with dCas9, which specifically includes the following steps: A) Preparation of Escherichia coli carrying pdCas9 K12MG1655 Determination of CRISPRi effects in chemically competent cells.
[0056] B) Plasmids pTargetF (expressing sgRNA-ampC), pTargetT, and pTarget-tg-ampC were transformed into these competent cells respectively.
[0057] C) Cells were grown in Luria-Bertani medium supplemented with kanamycin (50 μg / mL), spectromycin (50 μg / mL), and 0.4 mM IPTG at 30 ˚C for 24 hours.
[0058] D) After incubation, total RNA was extracted from harvested cells and then reverse transcribed into cDNA using the qScript Flex cDNA Kit.
[0059] E) The resulting cDNA was then used as a template for quantitative real-time PCR using ampC Designed gene-specific primers were used.
[0060] F) Optimize qPCR conditions for each target to accurately quantify CRISPRi-mediated knockdown efficiency.
[0061] (6) qPCR further revealed significant differences in expression levels, with the chimeric SeptgRNA expressing significantly higher levels than its sgRNA-ampC. Figure 4 shown.
[0062] Example 2: Targeting Escherichia coli using novel chimeric tgRNA ompA (1) Using the CRISPR / Cas9 sgRNA mutagenesis kit, target Escherichia coli ompA The guide N20 region of the gene (caacaaagcaaccctgaaac) was inserted into the pTargetF vector (Addgene #62226) to construct sgRNA targeting this gene.
[0063] (2) Construct the pTargetF vector containing SeptgRNA and transform it into Escherichia coli K12MG1655 expressed in strains.
[0064] A) This sequence was cloned into the pTargetF vector downstream of the pij23115 promoter and upstream of the rrnc terminator using SpeI and PstI restriction enzymes to generate the pTargetT vector, which is expressed as Figure 2 As shown in A; B) To generate chimeric SeptgRNAs, the targeting locus was amplified from pTargetF containing the sgRNA. ompA The sgRNA sequence was cloned into the SalI and AatII sites of the pTargetT vector to obtain the pTarget-tg vector, which was expressed as Figure 2 As shown in B.
[0065] C) Use of E. coli DH5α strain as the cloning host.
[0066] (3) A novel SeptgRNA with an optimized sgRNA inserted into the anticodon arm of SeptRNA ( ompA ),like Figure 1 As shown, the sequence is as follows: gcccggauagcucagucgguagagcagcggccgaguaauuuacgucgaccaacaaagcaaccctgaaacguuuuagagcuagaaauagcaguuaaaauaaggcuaguccguuau caacuugaaaaaguggcaccgagucggugcgacgucgaugguugcggccgcggguccaggguucaagucccuguucgggcgccacagcugcagauccuuagcgaaagcuaagga B) Transformation of pdCas into E. coli K12MG1655 in competent cells.
[0067] C) Cells were cultured in Luria-Bertani medium supplemented with kanamycin (50 μg / mL) and 0.4 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at 30 ˚C for 24 hours to induce dCas9 expression under controlled conditions.
[0068] D) The cells were then harvested and resuspended in PBS, pH 7.4.
[0069] E) After sonication and centrifugation, the supernatant containing dCas9 protein was loaded onto a 10% SDS-PAGE gel for electrophoresis.
[0070] F) Transfer the protein to a polyvinylidene difluoride (PVDF) membrane using a standard wet transfer system.
[0071] G) The membrane was then blocked with 5% nonfat milk for 1 hour at room temperature and then incubated with anti-Cas9 mouse monoclonal antibody (1:1000 dilution) at 4°C overnight.
[0072] H) After washing, HRP-conjugated rabbit anti-mouse antibody was added and detected using ECL Western Blot Luminol reagent.
[0073] (4) Detect the expression of tgRNA by Northern blot, such as Figure 2 As shown in C.
[0074] A) The dCas vector was constructed in the same manner as in Example 1, and the dCas9 protein was expressed and verified.
[0075] B) Transformation of pdCas into E. coli K12MG1655 in competent cells.
[0076] C) Cells were cultured in Luria-Bertani medium supplemented with kanamycin (50 μg / mL) and 0.4 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at 30 ˚C for 24 hours to induce dCas9 expression under controlled conditions.
[0077] D) The cells were then harvested and resuspended in PBS, pH 7.4.
[0078] E) After sonication and centrifugation, the supernatant containing dCas9 protein was loaded onto a 10% SDS-PAGE gel for electrophoresis.
[0079] F) Transfer the protein to a polyvinylidene difluoride (PVDF) membrane using a standard wet transfer system.
[0080] G) The membrane was then blocked with 5% nonfat milk for 1 hour at room temperature and then incubated with anti-Cas9 mouse monoclonal antibody (1:1000 dilution) at 4°C overnight.
[0081] H) After washing, HRP-conjugated rabbit anti-mouse antibody was added and detected using ECL Western Blot Luminol reagent.
[0082] (5) Using CRISPRi technology, DNA transcription is inhibited by co-expressing tgRNA with dCas9, which specifically includes the following steps: A) Preparation of Escherichia coli carrying pdCas9 K12MG1655 Determination of CRISPRi effects in chemically competent cells.
[0083] B) Plasmids pTargetF (expressing sgRNA-ompA), pTargetT, and pTarget-tg-ompA were transformed into these competent cells, respectively.
[0084] C) Cells were grown in Luria-Bertani medium supplemented with kanamycin (50 μg / mL), spectromycin (50 μg / mL), and 0.4 mM IPTG at 30 ˚C for 24 hours.
[0085] D) After incubation, total RNA was extracted from harvested cells and then reverse transcribed into cDNA using the qScript Flex cDNA Kit.
[0086] E) The resulting cDNA was then used as a template for quantitative real-time PCR using ompA Designed gene-specific primers were used.
[0087] F) Optimize qPCR conditions for each target to accurately quantify CRISPRi-mediated knockdown efficiency.
[0088] (6) qPCR further revealed significant differences in expression levels, with the chimeric SeptgRNA expressing significantly higher levels than its sgRNA-ompA, such as Figure 4 shown.
[0089] The results showed that co-expression of SeptgRNAs and dCas9 resulted in ampC and ompA The gene expression level was significantly decreased ( Figure 5 ). These findings suggest that SeptRNA scaffolds enhance CRISPRi efficiency, leading to more efficient gene regulation.
Claims
1. A method for obtaining tgRNA from a novel chimeric tRNA-sgRNA, characterized in that: The following steps are involved: (1) Select the guide N20 region of the target gene and insert it into the pTargetF vector (Addgene #62226) to construct the sgRNA; (2) constructing a functionalized tRNA scaffold by synthesizing a DNA sequence encoding a modified tRNA; (3) Using SpeI and PstI restriction endonucleases, clone the tRNA scaffold sequence synthesized in (2) into the pTargetF vector downstream of the pij23115 promoter and upstream of the rrnc terminator to generate the pTargetT vector; (4) The sgRNA sequence constructed in (1) was cloned into the SalI and AatII sites of the pTargetT vector to prepare the final pTarget-tg vector.
2. The method for obtaining tgRNA from the novel chimeric tRNA-sgRNA according to claim 1, characterized in that: The construction of sgRNA in step (1) includes target genes for all eukaryotic and prokaryotic organisms.
3. The method for obtaining tgRNA from the novel chimeric tRNA-sgRNA according to claim 1, characterized in that In step (1), the vector for inserting sgRNA can also be pUC19 or pBR322.
4. The method for obtaining tgRNA from the novel chimeric tRNA-sgRNA according to claim 1, characterized in that In step (2), to construct the tRNA scaffold, the synthesized DNA sequence is: 5'-`gcccggataggctcgcggtagagcgcgcgcggccgagtagtagcgacggtgcgatggttggcgcgcggggtcggtcagtcagtcatcagtcagggtcagtgaggcgcggacgcgcgagcgcgaggacggacggtgacgcggtgag-3'.
5. The method for obtaining tgRNA from the novel chimeric tRNA-sgRNA according to claim 1, characterized in that In step (2), the tRNA scaffold is derived from tRNA of any species of bacteria, fungi, animals, and plants.
6. The method for obtaining tgRNA from the novel chimeric tRNA-sgRNA according to claim 1, characterized in that In step (3), the tRNA sequence is cloned into the pTargetF vector to ensure the correct expression and function of the tRNA; the vector includes the pTargetF vector having the pij23115 promoter and the rrnc terminator. In addition to the pTargetF vector, the pBluescript or pGEM vector can also be used.
7. The method for obtaining tgRNA from the novel chimeric tRNA-sgRNA according to claim 1, characterized in that: The tgRNA vector synthesized in step (4) can target a single gene, or can use a linker to connect multiple identical or different tgRNAs to target multiple identical or different genes.
8. The method for obtaining tgRNA from the novel chimeric tRNA-sgRNA according to claims 1-8, characterized in that, The novel chimeric tgRNA method uses a CRISPR / Cas system, wherein the CRISPR / Cas gene editing system includes CRISPR / Cas3, CRISPR / Cas9, CRISPR / Cas12a (Cpf1), RISPR / Cas13a, and one of CRISPPR / Cas13a, CRISPR / Cas14, CasX and CasY.
